Evaluation of the impact of HDT adjunctive to standard therapy of TB (DS and MDRTB) in a pilot CT
To evaluate the potential impact of an HDT with anti-inflammatory effects as adjunct to WHO standard therapy for DS (treatment shortening) and MDR-TB (treatment improvement as well as shortening). The activities will be focused in to design, implement and perform the analysis of results of a RCT in order to evaluate the potential impact of an HDT with anti-inflammatory effects as adjunct to WHO standard therapy for DS (treatment shortening) and MDR-TB (treatment improvement as well as shortening).
Study of the pathogen and host factors influencing disease outcome and predicting response to treatment
To identify pathogen and host factors able to predict the course of the disease and its response to the intervention. Samples from TB patients will be used to identify biomarkers by studying relevant pathogen and host factors in TB patients samples and clinically validating biomarkers identified
Data science and systems biology approaches for patient stratification
To establish a stratification strategy through Systems Biology and Data Science based approaches which will be used to tailor optimal combinatorial treatment during clinical management.
Clinical, microbiological, HQoL data and other data from TB patients will be used to give relevance to the biomarkers study by analyzing the key molecular enclaves for their potential of classifying patients using a data science protocol.
To establish and implement the management infrastructure providing scientific and technical coordination for the activities of the Consortium partners as well as financial and contractual management of the Consortium
Communication, Dissemination and Exploitation
To ensure the maximum visibility and public awareness of project’s objectives, technologies and achievements taking into account sex and gender issues and RRI guidelines (Gender and Ethics).
To ensure compliance with the 'ethics requirements' set out in this work package.